Therapeutic effect of N-(4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea-induced rat mammary cancer.
Virgin Sprague--Dawley rats received a single i.v. injection of 40 mg N-methyl-N-nitrosourea (MNU)/kg body wt. at 50 days of age. After the first palpable mammary tumor reached 10 mm in size, the animals were sequentially allocated to one of 4 groups: (I) placebo diet, (II) 10 micrograms tamoxifen s.c. 3 times per week, (III) 3 mmol N-(4-hydroxyphenyl)retinamide (4-HPR)/kg diet, or (IV) both (II) and (III). Weekly measurements of initial tumors and subsequent tumors were made throughout the study. 4-HPR administration resulted in a complete regression (non-palpable state) of the first mammary tumor in 6 animals (22%) and partial regression or nonprogression in 5 others (19%). Tamoxifen alone induced only partial response in 9 animals (33%). 4-HPR and tamoxifen resulted in 19% total and 26% partial response. The data suggests therapeutic value of 4-HPR in MNU-induced rat mammary carcinoma.
Dowlatshahi
K
K
Rush-Presbyterian-St. Luke's Medical Center, Department of General Surgery, Chicago, IL 60612.
Mehta
R G
RG
Thomas
C F
CF
Dinger
N M
NM
Moon
R C
RC
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000473:pathology; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D017313:Fenretinide; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D008770:Methylnitrosourea; D051381:Rats; D012074:Remission Induction; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D014212:Tretinoin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013629:Tamoxifen; D017313:Fenretinide; D014212:Tretinoin; D008770:Methylnitrosourea